Page 24 - Syncona Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Syncona Limited, Director/PDMR Shareholding

  - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -     London, UK 11 May 2021 - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business highlights.   "Achilles made significant progress in the first quarter of 2021. We rep...

-3.90%   -  Morgan Advanced Materials PLC  (MGAMM.L)  Learn Forex: GBP Higher in Overnight Trade The British pound is the strongest major overnight, despite Nicola Sturgeon touting another Scottish referendum following the SNP’s fourth consecutive win. One would have expected the pound to suffer with the prospect of a new referendum, yet as the SNP fell just short of an outright majority, traders don’t appear to see it as an issue just yet. Boris Johnson condemned a second referendum, calling it “reckless”. GBP/USD broke marginally above 1.4000, yet volatility of the breakout...

7 May 2021 | 07:21am StockMarketWire.com - Syncona Ltd, a healthcare company focused on founding, building and funding a portfolio of global leaders in life science, has noted that its portfolio company, Gyroscope Therapeutics Holdings plc has postponed plans for its initial public offering in light of the current market conditions. "In light of market conditions, we have decided to postpone our planned initial public offering," said Khurem Farooq, Gyroscope Therapeutics’ chief executive officer. "Based on the positive feedback we have received from institutional investors on the strength...

Tel: +44 (0) 20 3727 1000   About Syncona Syncona's purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.   Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership wit...